Related Experiment Video

Updated: Jun 13, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors

Susan A J Vaziri1, Jenny Kim, Mahrukh K Ganapathi

  • 1Taussig Cancer Institute - R40, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, 44195, USA. vaziris@ccf.org

Current Oncology Reports
|April 29, 2010
PubMed

Insights

Targeting vascular endothelial growth factor (VEGF) with inhibitors is crucial for treating various cancers. Genetic variations in VEGF impact treatment outcomes and toxicity, paving the way for personalized cancer medicine.

Area of Science:

  • Oncology
  • Pharmacogenomics
  • Molecular Biology

Background:

  • Angiogenesis, the formation of new blood vessels, is essential for both normal tissue development and tumor growth.
  • Vascular Endothelial Growth Factor (VEGF) signaling is a critical pathway frequently dysregulated in tumors, driving neoangiogenesis.
  • Inhibiting VEGF signaling has led to approved therapies like bevacizumab and receptor tyrosine kinase inhibitors (TKIs) for several cancers.

Purpose of the Study:

  • To explore the role of genetic variability in VEGF and its receptors in cancer treatment.
  • To identify specific genetic markers that predict patient response and toxicity to anti-angiogenic therapies.
  • To highlight the potential for personalized medicine approaches in cancer treatment based on genetic profiles.

Main Methods:

  • Analysis of genetic variations, specifically single nucleotide polymorphisms (SNPs), within the VEGF pathway.
  • Correlation of identified SNPs with clinical outcomes, including treatment efficacy and adverse events.
  • Evaluation of treatment-induced hypertension in relation to specific VEGF genotypes.

Main Results:

  • Genotypic variations (SNPs) in VEGF and its receptors are associated with treatment outcomes in patients receiving anti-angiogenic therapies.
  • Specific SNPs in VEGF are linked to the development of hypertension as a side effect of angiogenesis inhibitor treatment.
  • These genetic markers offer insights into differential patient responses to VEGF-targeted drugs.

Conclusions:

  • Understanding genetic variability in the VEGF pathway is key to optimizing anti-angiogenic cancer therapy.
  • Identification of SNPs provides a basis for personalized medicine strategies to improve treatment efficacy and reduce toxicity.
  • Pharmacogenomic approaches utilizing VEGF SNPs can enhance the clinical management of cancers treated with angiogenesis inhibitors.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...